Answers are grounded in this paper and cite their sources.
Evidence on human T-cell lymphotropic virus (HTLV) seroreactivity and screening performance in hospital-based populations remains limited. This study aimed to characterize HTLV ELISA reactivity and its associated factors in Ningde, China, and to evaluate screening performance while accounting for partial verification. In this hospital-based cross-sectional study, 11,788 specimens from outpatients, inpatients, and physical examination (PE) participants were screened using ELISA. Verification was completed for all 153 reactive specimens and 489 selected non-reactive specimens. Multivariable logistic regression was used to identify factors independently associated with ELISA reactivity. Diagnostic accuracy was assessed within the verified subset and corrected for partial verification using S/CO-stratified extrapolation under specified assumptions about infection among unverified specimens. Exploratory receiver operating characteristic (ROC) analysis was performed in the verified subset to identify candidate cut-offs. Overall HTLV ELISA reactivity was 1.30% (153/11,788), with higher reactivity among outpatients and inpatients than among PE participants (1.59% vs. 0.46%; P < 0.001). Female sex, older age, and outpatient/inpatient status were independently associated with reactivity. Among the 642 verified specimens, sensitivity was 92.00%, specificity 96.95%, positive predictive value 90.20%, and negative predictive value 97.55%. Under the primary partial-verification correction assumptions, estimated sensitivity was 44.93% (95% credible interval, 27.79–63.31%), whereas specificity was 99.87% and positive predictive value remained 90.20%. Exploratory ROC analysis yielded an area under the curve of 0.9754 (95% confidence interval, 0.9578–0.9929) and a candidate S/CO cut-off of 0.4929. This study documented HTLV ELISA reactivity of 1.30% in a hospital-based population in Ningde, with higher reactivity among clinical patients than among PE participants. Despite a high positive predictive value, analyses accounting for partial verification suggested that the ELISA evaluated may miss a substantial proportion of infections. The extent of missed detection remains uncertain because corrected estimates depend on assumptions about unverified specimens. More complete or representative verification is needed to clarify screening sensitivity, and the exploratory cut-offs require independent validation before clinical use.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: